Polyneuropathy, inflammatory demyelinating, chronic

Summary

Polyneuropathy, inflammatory demyelinating, chronic (MONDO:0100169) is a disease and 22 clinical trials. Top therapeutic interventions include efgartigimod alfa, rituximab, and fibrinogen, human. A subtype of Guillain-Barre syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 22

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polyneuropathy, inflammatory demyelinating, chronic
Mondo ID	MONDO:0100169
GARD	0026072
Is cancer (heuristic)	no

Also known as: CIDP

Disease family

This is a subtype of Guillain-Barre syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › autoimmune disorder of the nervous system › autoimmune disorder of peripheral nervous system › Guillain-Barre syndrome › polyneuropathy, inflammatory demyelinating, chronic

Related subtypes (10): Guillain-Barre syndrome, familial, pharyngeal-cervical-brachial variant of Guillain-Barre syndrome, paraparetic variant of Guillain-Barre syndrome, acute pure sensory neuropathy, autoimmune autonomic ganglionopathy, acute sensory ataxic neuropathy, facial diplegia with paresthesias, acute inflammatory demyelinating polyradiculoneuropathy, acute motor and sensory axonal neuropathy, acute motor axonal neuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 22.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	13
PHASE3	6
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06290128	PHASE3	RECRUITING	A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06714838	PHASE3	RECRUITING	Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
NCT06859099	PHASE3	ENROLLING_BY_INVITATION	Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06920004	PHASE3	RECRUITING	A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT07091630	PHASE3	RECRUITING	A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07540221	PHASE3	RECRUITING	A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT04881682	PHASE2	RECRUITING	Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT00962429	PHASE2	COMPLETED	Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
NCT05584631	PHASE1	RECRUITING	IVIG vs SCIG in CIDP
NCT04777734	Not specified	AVAILABLE	Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05004493	Not specified	RECRUITING	Biorepository and Registry for Plasma Exchange Patients
NCT06968975	Not specified	RECRUITING	Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
NCT07006597	Not specified	NOT_YET_RECRUITING	Vitaccess Real CIDP Registry
NCT07264426	Not specified	RECRUITING	Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT01655394	Not specified	UNKNOWN	Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
NCT01847937	Not specified	COMPLETED	Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
NCT02629796	Not specified	COMPLETED	Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT03460951	Not specified	COMPLETED	Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC)
NCT03801135	Not specified	UNKNOWN	Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
NCT04249752	Not specified	UNKNOWN	Biomarkers in Polyradiculoneuropathies
NCT05614128	Not specified	TERMINATED	Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP
NCT05723848	Not specified	COMPLETED	Electronic Monitoring of Disease Activity in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EFGARTIGIMOD ALFA	4	2
RITUXIMAB	4	1
FIBRINOGEN, HUMAN	3	1
LIPOIC ACID, ALPHA	3	1
RILIPRUBART	3	1
EMPASIPRUBART	2	1
THIOCTIC ACID	0	1